Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin
- 27 June 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Apoptosis
- Vol. 11 (9), 1503-1512
- https://doi.org/10.1007/s10495-006-8896-3
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Synthetic Triterpenoids Cooperate with Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand to Induce Apoptosis of Breast Cancer CellsCancer Research, 2005
- HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivoBritish Journal of Cancer, 2005
- Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonistsThe Lancet Oncology, 2004
- The Synthetic Ligand of Peroxisome Proliferator-Activated Receptor-γ Ciglitazone Affects Human Glioblastoma Cell LinesJournal of Pharmacology and Experimental Therapeutics, 2004
- An Inducible Pathway for Degradation of FLIP Protein Sensitizes Tumor Cells to TRAIL-induced ApoptosisJournal of Biological Chemistry, 2002
- Selective Expression of FLIP in Malignant Melanocytic Skin LesionsJournal of Investigative Dermatology, 2001
- Increased expression of cFLIPL in colonic adenocarcinomaThe Journal of Pathology, 2001
- Locoregional Apo2L/TRAIL Eradicates Intracranial Human Malignant Glioma Xenografts in Athymic Mice in the Absence of NeurotoxicityBiochemical and Biophysical Research Communications, 1999
- Safety and antitumor activity of recombinant soluble Apo2 ligandJCI Insight, 1999
- APO2 ligand: a novel lethal weapon against malignant glioma?FEBS Letters, 1998